TRDX and Genesis to Pursue Objectives Separately
November 26 2010 - 3:30PM
Marketwired
SciMeDent Health, Corp. f/k/a Trend Exploration, Inc. ("TRDX" or
the "Company") (PINKSHEETS: TRDX)
After a very careful, extensive and exhaustive search for
capital in order to fund the Genesis Sub-license, TRDX board and
management have reached the unfortunate conclusion that such
capital for early stage biotech is in short supply. It is the
opinion of both management teams that is in the best interest of
both TRDX and Genesis that each party pursue its objectives on a
separate course and therefore have entered into a mutual release
agreement. TRDX management is still firmly of the belief that
Genesis' technology is quite leading edge and that under different
market conditions would have been more successful in meeting its
financing obligations.
About SCIMEDENT f/k/a Trend Exploration,
Inc. (PINKSHEETS: TRDX)
SciMeDent (www.scimedenthealth.com) is a company focused on
being a leading developer and marketer of products and services for
medicine, dentistry and life sciences. SciMeDent plans to achieve
growth initially through mergers and acquisitions.
Cautionary Statement Regarding Forward-Looking Statements
A number of statements contained in this press release are
forward-looking statements. These forward-looking statements
involve a number of risks and uncertainties, including the
sufficiency of existing capital resources, technological or
industry changes and uncertainties related to the development of
the Company's business model. The actual results the Company may
achieve could differ materially from any forward-looking statements
due to such risks and uncertainties.
Contact: SciMeDent Health Corp. f/k/a Trend Exploration, Inc.
www.scimedenthealth.com dmyers@cadenceconsultingllc.com
1-866-383-1374
Trend Exploration (PK) (USOTC:TRDX)
Historical Stock Chart
From Dec 2024 to Jan 2025
Trend Exploration (PK) (USOTC:TRDX)
Historical Stock Chart
From Jan 2024 to Jan 2025